drugset / Trial / NCT02209701

Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors

NCT02209701

Phase 1 Terminated 3 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to determine the steady-state pharmacokinetics and urinary excretion of porfiromycin and major metabolites in head and neck cancer and other cancer patients with solid tumors who receive radiation therapy.

Timeline

Start
1999-12
Primary completion
2000-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Porfiromycin Small molecule